The development of the oncology drug pipeline originates fromthe mechanisms underlying the emergence of drug resistance in cancer cells, exploring novel strategies for designing anti-cancer drugs, and developing drug molecules that can either block the formation of resistance or eradicate drug-resistant cancer cells.